mHSPC COE

Maximizing Survival in Metastatic Hormone-Sensitive Prostate Cancer: The Role of Triplet Therapy - Kelvin Moses

Details
Zach Klaassen and Kelvin Moses discuss the continuum of care for metastatic hormone-sensitive prostate cancer, focusing on triplet therapy. Dr. Moses highlights the ideal patient profile for this treatment, emphasizing collaboration between urology and medical oncology. They stress the manageable nature of chemotherapy and its finite duration. The conversation extends to disparities in prostate ca...

The Role of Urologists in Managing De Novo Metastatic Prostate Cancer - Benjamin Lowentritt

Details
Alicia Morgans engages in a discussion with Benjamin Lowentritt, focusing on comprehensive care for prostate cancer patients, particularly those with de novo metastatic hormone-sensitive disease. Dr. Lowentritt shares a patient case illustrating the challenges and strategies in managing such cases over time. They emphasize the importance of multidisciplinary teams and seamless communication betwee...

Teamwork and Trust: Keys to Seamless Prostate Cancer Care Across Specialties - Paul Eber & Brad Somer

Details
Alicia Morgans hosts a discussion with Paul Eber and Brad Somer to explore the collaborative management of metastatic hormone-sensitive prostate cancer cases. They highlight a unique partnership between urology and medical oncology in Memphis, Tennessee, emphasizing the importance of teamwork in treating patients, especially in underserved areas. Dr. Eber shares his experience with patients presen...

Best Practices for Successfully Implementing Triplet Therapy in mHSPC - Christopher Pieczonka

Details
Christopher Pieczonka discusses the management of metastatic hormone-sensitive prostate cancer with a focus on triple therapy. Dr. Pieczonka emphasizes that androgen deprivation therapy (ADT) is no longer the standard of care as monotherapy for metastatic prostate cancer, citing the ARASENS study's results, which demonstrate the overall survival benefit of adding docetaxel and Nubeqa to ADT. He su...

Treating Metastatic Hormone-Sensitive Prostate Cancer: Beyond Counting Metastases - Karim Fizazi

Details
Alicia Morgans discusses the evolving strategies for treating metastatic hormone-sensitive prostate cancer (mHSPC) with Karim Fizazi. Professor Fizazi critiques the traditional method of classifying metastatic disease by the volume of metastases, advocating for a more nuanced approach. He highlights recent phase three trials that suggest a shift away from simply categorizing disease into low and h...

Urology-Oncology Collaboration: Keys to Optimal Care in Metastatic Prostate Cancer - Damian Sorce & Manojkumar Bupathi

Details
Alicia Morgans hosts a discussion with Damian Sorce, a urologist, and Manoj Bupathi, a medical oncologist, on their collaboration in treating patients with metastatic hormone-sensitive prostate cancer. Dr. Sorce shares a case of a newly diagnosed patient with advanced disease, emphasizing the importance of immediate communication and coordination between urology and medical oncology for starting t...

Coordinating Complex Care in High-Volume mHSPC Through Multidisciplinary Communication - Jonathan Henderson & Sunil Kakadia

Details
Alicia Morgans convenes a discussion on managing high-volume metastatic hormone-sensitive prostate cancer, bridging the practices of urology and medical oncology with Jonathan Henderson and Sunil Kakadia, a medical oncologist from Genesis Oncology. They emphasize the importance of collaborative care in treating complex cases, like a patient presenting with high PSA levels, highlighting the multidi...

Optimizing mHSPC Care and Collaboration for Triplet Therapy - Jason Hafron & Elisabeth Heath

Details
Zach Klaassen facilitates a conversation on the continuum of care in metastatic hormone-sensitive prostate cancer (mHSPC) with Jason Hafron and Elisabeth Heath. The discussion underscores the importance of collaboration between urology and medical oncology, particularly in administering triplet therapy. Dr. Hafron highlights the evolution of their partnership, emphasizing shared knowledge and pati...

ARASENS Subgroup Analysis on Triplet Therapy Improves Outcomes for Black Patients with mHSPC, Journal Club - Rashid Sayyid & Zachary Klaassen

Details
Rashid Sayyid and Zach Klaassen delve into the significance of racial disparities in prostate cancer treatment through a subgroup analysis of the ARASENS trial, which notably focused on Black patients. This pivotal trial assessed the efficacy of adding darolutamide to ADT and docetaxel in metastatic hormone-sensitive prostate cancer, revealing that Black patients, despite historically higher morta...

Examining Prostate Cancer Survival Outcomes by Patient Age and Treatment Type in Patients with Metastatic Hormone-Sensitive Prostate Cancer - Alicia Morgans

Details
Alicia Morgans presents a meta-analysis, undertaken with colleagues, analyzing 14 phase three trials on treatment intensification in metastatic hormone-sensitive prostate cancer. The study scrutinizes outcomes between older and younger patients, revealing that older patients exhibit a slightly diminished benefit from intensified treatments compared to their younger counterparts. Despite this, the...